Drugs play a central role in modern medicine, but bringing new ones to market is a lengthy, expensive process. Industry and academia are exploring ways to streamline the complex drug development pipeline with artificial intelligence (AI). However, efficiently analysing chemistry and biology have favoured neural networks, whose structure naturally mimics that of molecules. Regina Barzilay, executive director of MIT Jameel Clinic, the epicentre of AI and health at the Massachusetts Institute of Technology, predicts that neural networks is an area "that's going to grow for the field, and we will see a lot of computer science discoveries along the way".
